MedTrace Logo

Fatıgue Management and Qualıty of Lıfe

NCT07754565 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-10

No results posted yet for this study

Summary

Aim: This study was conducted as a randomized controlled experimental study to determine the effect of integrative therapies on fatigue management and qualiy of life in cancer patients receiving immunotherapy.

Materials and Methods: In the study 60 patients, 30 in the intervention group and 30 in the control group were included in the sample. The intervention group was given Pranayama breathing exercise for 20 minutes before immunotherapy treatment and listened to music during immunotherapy. Study data were collected using the "Patient Information Form ", "FACT-G Quality of Life Scale " and "Hirai Cancer Fatigue Scale ". Appropriate statistical methods were used to analyze the data.

Conditions

Interventions

OTHER

Pranayama Group

Patient Information Form, FACT-G Quality of Life Scale and Hirai Cancer Fatigue Scale were filled in the first interview. Patients in the intervention group were given Pranayama breathing exercise by the practitioner for 20 minutes before immunotherapy and then were allowed to listen to music with headphones during immunotherapy treatment. The patient was contacted by telephone for the patient to listen to music and do pranayama exercise at least 3 days a week for 8 weeks following the treatment. The application was repeated before each immunotherapy and the application was continued for a total of 8 weeks. The FACT-G Quality of Life Scale and Hirai Cancer Fatigue Scale were completed by face-to-face interviews with the patient in the fourth and eighth weeks.

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Principal Investigators

  • Gamze Temiz, Dr · Istanbul University - Cerrahpasa

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2022-11-01
Completion
2024-02-28

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07754565 on ClinicalTrials.gov